Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00783718 · ClinicalTrials.gov registry record · Phase 3
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis
A Phase 3 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 895
- Enrollment target
NCT00783718 is a Phase 3 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 895 participants.
The verdict
NCT00783718, a Phase 3 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 895 participants
- Enrollment target
Study Summary
The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks.
Interventions
- OTHER Placebo
- DRUG vedolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 895 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00783718
The ClinicalTrials.gov registry entry for NCT00783718 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 895 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00783718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00783718 about?
NCT00783718 is a clinical study titled "Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis". The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks.
What is the current status of trial NCT00783718?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 895 participants. The study started on 2009-01. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00783718?
The interventions under investigation include: Placebo (OTHER), vedolizumab (DRUG).
Who is sponsoring clinical trial NCT00783718?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.